Alvotech Gains Additional $75 Mln Loan Facility From GoldenTree

July 01, 2026 — 07:05 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Alvotech (ALVO), a biotechnology company, on Wednesday announced the amendment of an existing credit agreement with GoldenTree Asset Management LP and other leaders of Alvotech to gain access to an additional $75 million in capital.

Alvotech entered a loan facility agreement with GoldenTree in December 2025 for an initial amount of $100 million, with a monthly interest rate of 12.5% payable in cash. The loan facility is expected to mature on December 31, 2027.

The new loan facility supplements the $165 million acquired via a private placement reported on June 18, 2026, bringing the total capital accessible to the company at $240 million.

The new capital may be utilized by the company in advancing biologics license applications (BLAs) for various developing biosimilars. The BLA for an Entyvio biosimilar, one of the lead candidates of Alvotech, was recently accepted for review by the FDA.

ALVO closed Tuesday at $3.69, down 0.81%. In the pre-market, shares are trading at $3.80, up 2.98%.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Alvotech Gains Additional $75 Mln Loan Facility From GoldenTree

Tags

Latest Articles